No connection

Search Results

BGM vs IART

BGM
BGM Group Ltd.
BEARISH
Price
$3.72
Market Cap
$746.3M
Sector
Healthcare
AI Confidence
85%
IART
Integra LifeSciences Holdings Corporation
NEUTRAL
Price
$9.90
Market Cap
$771.6M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
BGM
--
IART
--
Forward P/E
BGM
--
IART
3.86
P/B Ratio
BGM
2.01
IART
0.74
P/S Ratio
BGM
24.99
IART
0.47
EV/EBITDA
BGM
-29.15
IART
8.54

Profitability

Gross Margin
BGM
2.92%
IART
56.23%
Operating Margin
BGM
-5.41%
IART
12.44%
Profit Margin
BGM
-26.32%
IART
-31.58%
ROE
BGM
-16.52%
IART
-39.9%
ROA
BGM
-3.84%
IART
2.39%

Growth

Revenue Growth
BGM
-56.9%
IART
-1.7%
Earnings Growth
BGM
0.0%
IART
--

Financial Health

Debt/Equity
BGM
0.0
IART
1.95
Current Ratio
BGM
7.05
IART
2.54
Quick Ratio
BGM
5.94
IART
1.19

Dividends

Dividend Yield
BGM
--
IART
--
Payout Ratio
BGM
0.0%
IART
0.0%

AI Verdict

BGM BEARISH

The Advanced Deterministic Scorecard shows a Piotroski F-Score of 6/9, indicating stable financial health, but the absence of an Altman Z-Score and negative profitability metrics raise concerns. The company is unprofitable with a -26.32% profit margin, -5.41% operating margin, and negative ROE and ROA, while revenue has collapsed by 56.90% year-over-year. Valuation multiples are extremely high with a Price/Sales ratio of 24.99 despite deteriorating fundamentals, and the stock has lost 90.8% of its value over five years. Although the balance sheet shows no debt and strong liquidity ratios, the lack of earnings, cash flow data, and analyst coverage suggests high uncertainty and limited investor confidence.

Strengths
Piotroski F-Score of 6/9 indicates stable financial health relative to distressed peers
Exceptionally strong liquidity with a Current Ratio of 7.05 and Quick Ratio of 5.94
Zero debt (Debt/Equity = 0.00), reducing solvency risk
Risks
Severe profitability issues: -26.32% profit margin and -16.52% ROE
Catastrophic revenue decline of -56.90% YoY, far worse than peer average
Price/Sales of 24.99 is extremely high for a shrinking, unprofitable company
IART NEUTRAL

IART presents as a classic deep-value turnaround candidate with a stable Piotroski F-Score of 6/9, indicating reasonable operational health despite severe price depreciation. The company is trading at a significant discount to book value (P/B 0.74) and possesses a very low forward P/E of 3.86, suggesting the market has over-priced the risk. However, negative net profit margins (-31.58%) and stagnant revenue growth (-1.70%) offset the valuation appeal. The stark contrast between the current price ($9.90) and the analyst target ($15.57) indicates potential upside, but the bearish technical trend remains a primary headwind.

Strengths
Deep value valuation with P/B of 0.74 and P/S of 0.47
Strong short-term liquidity with a Current Ratio of 2.54
Stable financial health baseline (Piotroski F-Score 6/9)
Risks
Severe long-term price erosion (-85.7% over 5 years)
Negative net profit margins (-31.58%) impacting bottom-line stability
Stagnant to declining revenue growth (YoY -1.70%)

Compare Another Pair

BGM vs IART: Head-to-Head Comparison

This page compares BGM Group Ltd. (BGM) and Integra LifeSciences Holdings Corporation (IART) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile